Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 478049, 17 pages
http://dx.doi.org/10.1155/2013/478049
Research Article

The Protective Effects of Cobra Venom from Naja naja atra on Acute and Chronic Nephropathy

Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Soochow University School of Pharmaceutical Science, 199 Ren Ai Road, Suzhou 215123, China

Received 15 February 2013; Revised 23 May 2013; Accepted 23 May 2013

Academic Editor: Angelo Antonio Izzo

Copyright © 2013 Shu-Zhi Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Wang, Y. P. Wang, Y. C. Tay, and D. C. Harris, “Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events,” Kidney International, vol. 58, no. 4, pp. 1797–1804, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Ozbek, “Induction of oxidative stress in kidney,” International Journal of Nephrology, vol. 2012, Article ID 465897, 9 pages, 2012. View at Publisher · View at Google Scholar
  3. N. Venkatesan, D. Punithavathi, and V. Arumugam, “Curcumin prevents adriamycin nephrotoxicity in rats,” The British Journal of Pharmacology, vol. 129, no. 2, pp. 231–234, 2000. View at Google Scholar · View at Scopus
  4. K. Yasui and A. Baba, “Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation,” Inflammation Research, vol. 55, no. 9, pp. 359–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Giera, H. Lingeman, and W. M. A. Niessen, “Recent advancements in the LC- and GC-based analysis of malondialdehyde (MDA): a brief overview,” Chromatographia, vol. 75, no. 9-10, pp. 433–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K. A. D. Sauter, L. J. Wood, J. Wong, M. Iordanov, and B. E. Magun, “Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome,” Cancer Biology and Therapy, vol. 11, no. 12, pp. 1008–1016, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Lipniacki, P. Paszek, A. R. Brasier, B. Luxon, and M. Kimmel, “Mathematical model of NF-κB regulatory module,” Journal of Theoretical Biology, vol. 228, no. 2, pp. 195–215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M. S. Hayden and S. Ghosh, “Shared principles in NF-κB signaling,” Cell, vol. 132, no. 3, pp. 344–362, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. P. Singh, A. J. Singh, and N. Singh, “Pharmacological investigations of Punica granatum in glycerol-induced acute renal failure in rats,” Indian Journal of Pharmacology, vol. 43, no. 5, pp. 551–556, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. T. J. Soares, R. S. Costa, R. A. Volpini, C. G. A. da Silva, and T. M. Coimbra, “Long-term evolution of the acute tubular necrosis (ATN) induced by glycerol: role of myofibroblasts and macrophages,” International Journal of Experimental Pathology, vol. 83, no. 4, pp. 165–172, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Y. Khan, “Rhabdomyolysis: a review of the literature,” Netherlands Journal of Medicine, vol. 67, no. 9, pp. 272–283, 2009. View at Google Scholar · View at Scopus
  12. Y. Zurovsky, “Models of glycerol-induced acute renal failure in rats,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 4, no. 3, pp. 213–228, 1993. View at Google Scholar · View at Scopus
  13. C. W. Vogel and D. C. Fritzinger, “Cobra venom factor: structure, function, and humanization for therapeutic complement depletion,” Toxicon, vol. 56, no. 7, pp. 1198–1222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. G. N. Shi, Y. L. Liu, H. M. Lin et al., “Involvement of cholinergic system in suppression of formalin-induced inflammatory pain by cobratoxin,” Acta Pharmacologica Sinica, vol. 32, no. 10, pp. 1233–1238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. A. Barker, E. Ratcliffe, M. McLaughlin, A. Richards, and S. B. Dunnett, “A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease,” Journal of Neuroscience, vol. 20, no. 9, pp. 3415–3424, 2000. View at Google Scholar · View at Scopus
  16. A. Armugam, C. D. N. Cher, K. Lim, D. C. I. Koh, D. W. Howells, and K. Jeyaseelan, “A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis,” BMC Neuroscience, vol. 10, article 120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Sher, F. Giovannini, J. Boot, and B. Lang, “Peptide neurotoxins, small-cell lung carcinoma and neurological paraneoplastic syndromes,” Biochimie, vol. 82, no. 9-10, pp. 927–936, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. M. H. Park, H. S. Song, K. H. Kim et al., “Cobrotoxin inhibits NF-κB activation and target gene expression through reaction with NF-κB signal molecules,” Biochemistry, vol. 44, no. 23, pp. 8326–8336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Giorgi, M. M. Bernardi, and Y. Cury, “Analgesic effect evoked by low molecular weight substances extracted from Crotalus durissus terrificus venom,” Toxicon, vol. 31, no. 10, pp. 1257–1265, 1993. View at Publisher · View at Google Scholar · View at Scopus
  20. X. C. Pu, P. T. H. Wong, and P. Gopalakrishnakone, “A novel analgesic toxin (hannalgesin) from the venom of king cobra (Ophiophagus hannah),” Toxicon, vol. 33, no. 11, pp. 1425–1431, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. T. C. Qin, L. X. Yu, and Z. S. Wang, “Study on rectal mucosa absorption effects of cobra neurotoxins by I tracer labelling methods,” Journal of Zhejiang College of TCM, vol. 25, no. 5, pp. 55–56, 2001, translation from Chinese. View at Google Scholar
  22. C. Z. Zhu, H. Li, Q. P. Yang et al., “The clinical treatment of diabetic kidney capsule of Cobra venom,” Medicine and Pharmacy of Yunnan, vol. 18, pp. 460–461, 1997, translation from Chinese. View at Google Scholar
  23. K. Z. Zhu, Y. L. Liu, J. H. Gu, and Z. H. Qin, “Antinociceptive and anti-inflammatory effects of orally administrated denatured naja naja atra venom on murine rheumatoid arthritis models,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 616241, 10 pages, 2013. View at Publisher · View at Google Scholar
  24. P. Hu, Y. H. Qin, J. Pei, F. Y. Lei, B. Hu, and L. Lu, “Beneficial effect of all-trans retinoic acid (ATRA) on glomerulosclerosis rats via the down-regulation of the expression of α-smooth muscle actin: a comparative study between ATRA and benazepril,” Experimental and Molecular Pathology, vol. 89, no. 1, pp. 51–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C. J. Bowmer, M. G. Collis, and M. S. Yates, “Effect of the adenosine antagonist 8-phenyltheophylline on glycerol-induced acute renal failure in the rat,” The British Journal of Pharmacology, vol. 88, no. 1, pp. 205–212, 1986. View at Google Scholar · View at Scopus
  26. H. H. Chen, “Is cystatin C an important prognostic marker independent of renal function?” Journal of the American College of Cardiology, vol. 56, no. 23, pp. 1937–1938, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. H. Wang, L. Wang, Y. Zhou et al., “Prevalence and control of dyslipidaemia among diabetic patients with microalbuminuria in a Chinese hospital,” Diabetes and Vascular Disease Research, vol. 10, no. 2, pp. 169–178, 2013. View at Publisher · View at Google Scholar
  28. L. E. Schlanger, J. L. Bailey, and J. M. Sands, “Electrolytes in the aging,” Advances in Chronic Kidney Disease, vol. 17, no. 4, pp. 308–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Kamgang, A. F. Foyet, J. L. Essame, and J. Y. Ngogang, “Effect of methanolic fraction of Kalanchoe crenata on metabolic parameters in adriamycin-induced renal impairment in rats,” Indian Journal of Pharmacology, vol. 44, no. 5, pp. 566–570, 2012. View at Publisher · View at Google Scholar
  30. N. Nagano, S. Miyata, S. Obana et al., “Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency,” Nephrology Dialysis Transplantation, vol. 16, no. 9, pp. 1870–1878, 2001. View at Google Scholar · View at Scopus
  31. Y. Qi, H. Xiao, C. Xu, X. Tian, H. Wu, and W. Shen, “Cyprinus carpio decoction improves nutrition and immunity and reduces proteinuria through nephrin and CD2AP expressions in rats with adriamycin-induced nephropathy,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 237482, 8 pages, 2012. View at Publisher · View at Google Scholar
  32. K. Zandi-Nejad, A. A. Eddy, R. J. Glassock, and B. M. Brenner, “Why is proteinuria an ominous biomarker of progressive kidney disease?” Kidney International, Supplement, vol. 66, no. 92, pp. S76–S89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Kerjaschki, “Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis,” Journal of Clinical Investigation, vol. 108, no. 11, pp. 1583–1587, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Abbate, C. Zoja, and G. Remuzzi, “How does proteinuria cause progressive renal damage?” Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 2974–2984, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Cao, Y. Wang, D. Zheng et al., “IL-10/TGF-β-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis,” Journal of the American Society of Nephrology, vol. 21, no. 6, pp. 933–942, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Lipcsey, M. Furebring, S. Rubertsson, and A. Larsson, “Significant differences when using creatinine, modification of diet in renal disease, or cystatin C for estimating glomerular filtration rate in ICU patients,” Upsala Journal of Medical Sciences, vol. 116, no. 1, pp. 39–46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Google Scholar · View at Scopus
  38. Z. Lin, Z. Zhou, Y. Liu et al., “Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese,” PLoS ONE, vol. 6, no. 4, Article ID e18398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. G. van Pottelbergh, L. van Heden, C. Matheï, and J. Degryse, “Methods to evaluate renal function in elderly patients: a systematic literature review,” Age and Ageing, vol. 39, no. 5, Article ID afq091, pp. 542–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Fliser and E. Ritz, “Serum cystatin C concentration as a marker of renal dysfunction in the elderly,” The American Journal of Kidney Diseases, vol. 37, no. 1, pp. 79–83, 2001. View at Google Scholar · View at Scopus
  41. B. A. Perkins, R. G. Nelson, B. E. P. Ostrander et al., “Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study,” Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1404–1412, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Takemura, K. Yoshioka, N. Aya et al., “Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases,” Kidney International, vol. 43, no. 4, pp. 918–927, 1993. View at Google Scholar · View at Scopus
  43. D. C. Wheeler and R. S. Chana, “Interactions between lipoproteins, glomerular cells and matrix,” Mineral and Electrolyte Metabolism, vol. 19, no. 3, pp. 149–164, 1993. View at Google Scholar · View at Scopus
  44. H. Sato, S. Suzuki, H. Kobayashi, S. Ogino, A. Inomata, and M. Arakawa, “Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE,” Clinical Nephrology, vol. 36, no. 3, pp. 127–133, 1991. View at Google Scholar · View at Scopus
  45. N. R. Shah and F. Dumler, “Hypoalbuminaemia—a marker of cardiovascular disease in patients with chronic kidney disease stages II–IV,” International Journal of Medical Sciences, vol. 5, no. 6, pp. 366–370, 2008. View at Google Scholar · View at Scopus
  46. J. Xie, K. Kiryluk, W. Wang et al., “Predicting progression of IgA nephropathy: new clinical progression risk score,” PLoS ONE, vol. 7, no. 6, Article ID e38904, 2012. View at Publisher · View at Google Scholar
  47. W. Saka, R. Akhigbe, O. Popoola, and O. Oyekunle, “Changes in serum electrolytes, urea, and creatinine in Aloe vera-treated rats,” Journal of Young Pharmacists, vol. 4, no. 2, pp. 78–81, 2012. View at Publisher · View at Google Scholar
  48. S. L. Furth, A. G. Abraham, J. Jerry-Fluker et al., “Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 9, pp. 2132–2140, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Mathew, K. S. Tustison, T. Sugatani, L. R. Chaudhary, L. Rifas, and K. A. Hruska, “The mechanism of phosphorus as a cardiovascular risk factor in CKD,” Journal of the American Society of Nephrology, vol. 19, no. 6, pp. 1092–1105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Ruiz-Ortega and A. Ortiz, “Angiotensin II and reactive oxygen species,” Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1258–1260, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. C. M. Elks, N. Mariappan, M. Haque, A. Guggilam, D. S. A. Majid, and J. Francis, “Chronic NF-κB blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR,” The American Journal of Physiology, vol. 296, no. 2, pp. F298–F305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. E. D. Lamprecht and C. A. Williams, “Biomarkers of antioxidant status, inflammation, and cartilage metabolism are affected by acute intense exercise but not superoxide dismutase supplementation in horses,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 920932, 2012. View at Publisher · View at Google Scholar
  53. P. B. Walter, E. B. Fung, D. W. Killilea et al., “Oxidative stress and inflammation in iron-overloaded patients with β-thalassaemia or sickle cell disease,” The British Journal of Haematology, vol. 135, no. 2, pp. 254–263, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. P. J. Barnes and M. Karin, “Nuclear factor-κB—a pivotal transcription factor in chronic inflammatory diseases,” The New England Journal of Medicine, vol. 336, no. 15, pp. 1066–1071, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Tian, Y. Zhang, B. A. Luxon et al., “Identification of NF-κB-dependent gene networks in respiratory syncytial virus-infected cells,” Journal of Virology, vol. 76, no. 13, pp. 6800–6814, 2002. View at Publisher · View at Google Scholar · View at Scopus